Published in Pharmacogenomics J on April 21, 2009
Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk. Cell Cycle (2011) 1.64
CYP2C8*3 predicts benefit/risk profile in breast cancer patients receiving neoadjuvant paclitaxel. Breast Cancer Res Treat (2012) 1.23
Cytochrome P450 2C9-CYP2C9. Pharmacogenet Genomics (2010) 1.16
Cytochrome P450 2C8 pharmacogenetics: a review of clinical studies. Pharmacogenomics (2009) 1.15
Multi-ethnic distribution of clinically relevant CYP2C genotypes and haplotypes. Pharmacogenomics J (2012) 0.97
African variation at Cytochrome P450 genes: Evolutionary aspects and the implications for the treatment of infectious diseases. Evol Med Public Health (2013) 0.95
Mini-haplotypes as lineage informative SNPs and ancestry inference SNPs. Eur J Hum Genet (2012) 0.84
PharmGKB summary: very important pharmacogene information for cytochrome P450, family 2, subfamily C, polypeptide 8. Pharmacogenet Genomics (2013) 0.80
CYP2C8 gene polymorphism and bisphosphonate-related osteonecrosis of the jaw in patients with multiple myeloma. Haematologica (2011) 0.80
Cytochrome P450 CYP 2C19*2 Associated with Adverse 1-Year Cardiovascular Events in Patients with Acute Coronary Syndrome. PLoS One (2015) 0.79
Linkage disequilibrium between the CYP2C19*17 and CYP2C8*2 alleles in populations of African descent. Eur J Clin Pharmacol (2010) 0.77
Proposed nomenclature for microhaplotypes. Hum Genomics (2016) 0.75
A fast and flexible statistical model for large-scale population genotype data: applications to inferring missing genotypes and haplotypic phase. Am J Hum Genet (2006) 28.32
Accounting for decay of linkage disequilibrium in haplotype inference and missing-data imputation. Am J Hum Genet (2005) 14.09
Implications of biogeography of human populations for 'race' and medicine. Nat Genet (2004) 3.34
Attenuation of isoproterenol-mediated vasodilatation in blacks. N Engl J Med (1995) 3.25
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Anal Bioanal Chem (2008) 2.24
Clinical consequences of cytochrome P450 2C9 polymorphisms. Clin Pharmacol Ther (2005) 1.83
Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid. Pharmacogenetics (2001) 1.83
Genetic analysis of the human cytochrome P450 CYP2C9 locus. Pharmacogenetics (1996) 1.67
Peripheral neuropathy induced by paclitaxel: recent insights and future perspectives. Curr Neuropharmacol (2006) 1.53
Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clin Pharmacol Ther (2005) 1.51
CYP2C8 polymorphisms in Caucasians and their relationship with paclitaxel 6alpha-hydroxylase activity in human liver microsomes. Biochem Pharmacol (2002) 1.49
Association of Paclitaxel pharmacokinetics with the development of peripheral neuropathy in patients with advanced cancer. Clin Cancer Res (2005) 1.33
Interethnic and intraethnic variability of CYP2C8 and CYP2C9 polymorphisms in healthy individuals. Mol Diagn Ther (2006) 1.33
Doxorubicin cardiotoxicity in African Americans. J Natl Med Assoc (2004) 1.32
Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet (2006) 1.29
Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res (2006) 1.29
Racial or ethnic differences in allele frequencies of single-nucleotide polymorphisms in the methylenetetrahydrofolate reductase gene and their influence on response to methotrexate in rheumatoid arthritis. Ann Rheum Dis (2006) 1.20
Pharmacogenetics of the major polymorphic metabolizing enzymes. Fundam Clin Pharmacol (2003) 1.17
Interindividual variability in ibuprofen pharmacokinetics is related to interaction of cytochrome P450 2C8 and 2C9 amino acid polymorphisms. Clin Pharmacol Ther (2004) 1.17
Linkage between the CYP2C8 and CYP2C9 genetic polymorphisms. Biochem Biophys Res Commun (2002) 1.15
Association of CYP2C8, CYP3A4, CYP3A5, and ABCB1 polymorphisms with the pharmacokinetics of paclitaxel. Clin Cancer Res (2005) 1.13
HAPLOT: a graphical comparison of haplotype blocks, tagSNP sets and SNP variation for multiple populations. Bioinformatics (2005) 1.10
Pharmacogenetics of the cytochromes P450. Curr Top Med Chem (2004) 1.05
Haplotype evolution of SLITRK1, a candidate gene for Gilles de la Tourette syndrome. Am J Med Genet B Neuropsychiatr Genet (2008) 0.99
Non-synonymous single nucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism. Biol Pharm Bull (2001) 0.98
Characterization of novel CYP2C8 haplotypes and their contribution to paclitaxel and repaglinide metabolism. Pharmacogenomics J (2007) 0.97
Genetic variation in the cytochrome P450 epoxygenase pathway and cardiovascular disease risk. Pharmacogenomics (2007) 0.96
Global patterns of variation in allele and haplotype frequencies and linkage disequilibrium across the CYP2E1 gene. Pharmacogenomics J (2008) 0.96
Functional role of Ile264 in CYP2C8: mutations affect haem incorporation and catalytic activity. Drug Metab Pharmacokinet (2008) 0.95
Pharmacogenomics of drug-metabolizing enzymes and drug transporters in chemotherapy. Methods Mol Biol (2008) 0.93
The complex global pattern of genetic variation and linkage disequilibrium at catechol-O-methyltransferase. Mol Psychiatry (2008) 0.90
Global pharmacogenetics: genetic substructure of Eurasian populations and its effect on variants of drug-metabolizing enzymes. Pharmacogenomics (2008) 0.90
Development and evaluation of a rapid and reliable method for cytochrome P450 2C8 genotyping. Clin Lab (2004) 0.87
Individualized pharmacotherapy with paclitaxel. Curr Opin Oncol (2007) 0.81
Severe pulmonary complications in African-American patient after bortezomib therapy. Am J Ther (2006) 0.81
CYP2C8 haplotype structures and their influence on pharmacokinetics of paclitaxel in a Japanese population. Pharmacogenet Genomics (2007) 0.80
Genetic structure of human populations. Science (2002) 30.91
A human genome diversity cell line panel. Science (2002) 14.11
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer. J Clin Oncol (2002) 13.81
Molecular definition of breast tumor heterogeneity. Cancer Cell (2007) 12.67
A signature of chromosomal instability inferred from gene expression profiles predicts clinical outcome in multiple human cancers. Nat Genet (2006) 7.16
Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma. Nat Genet (2012) 7.00
A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res (2008) 5.05
Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell (2008) 3.95
Hunter-gatherer genomic diversity suggests a southern African origin for modern humans. Proc Natl Acad Sci U S A (2011) 3.53
Implications of biogeography of human populations for 'race' and medicine. Nat Genet (2004) 3.34
The genetic structure of Pacific Islanders. PLoS Genet (2008) 3.31
Requirement for CDK4 kinase function in breast cancer. Cancer Cell (2006) 2.92
Intelligence, race, and genetics. Am Psychol (2005) 2.76
ALFRED: An allele frequency database for anthropology. Am J Phys Anthropol (2002) 2.67
A global perspective on genetic variation at the ADH genes reveals unusual patterns of linkage disequilibrium and diversity. Am J Hum Genet (2002) 2.60
Recursive SVM feature selection and sample classification for mass-spectrometry and microarray data. BMC Bioinformatics (2006) 2.53
HER2 and chromosome 17 effect on patient outcome in the N9831 adjuvant trastuzumab trial. J Clin Oncol (2010) 2.49
Evidence of positive selection acting at the human dopamine receptor D4 gene locus. Proc Natl Acad Sci U S A (2001) 2.48
Global diversity and evidence for coevolution of KIR and HLA. Nat Genet (2007) 2.40
Evolutionary dynamics of human Toll-like receptors and their different contributions to host defense. PLoS Genet (2009) 2.35
Bitter receptor gene (TAS2R38), 6-n-propylthiouracil (PROP) bitterness and alcohol intake. Alcohol Clin Exp Res (2004) 2.26
Differentiated cells are more efficient than adult stem cells for cloning by somatic cell nuclear transfer. Nat Genet (2006) 2.19
Low nucleotide diversity in chimpanzees and bonobos. Genetics (2003) 2.16
Impact of PTEN protein expression on benefit from adjuvant trastuzumab in early-stage human epidermal growth factor receptor 2-positive breast cancer in the North Central Cancer Treatment Group N9831 trial. J Clin Oncol (2013) 2.15
A role for the scaffolding adapter GAB2 in breast cancer. Nat Med (2005) 2.12
Vibratory Urticaria Associated with a Missense Variant in ADGRE2. N Engl J Med (2016) 2.09
Efficacy of pegfilgrastim and darbepoetin alfa as hematopoietic support for dose-dense every-2-week adjuvant breast cancer chemotherapy. J Clin Oncol (2005) 2.09
Inferring the demographic history of African farmers and pygmy hunter-gatherers using a multilocus resequencing data set. PLoS Genet (2009) 2.07
Trastuzumab-induced HER reprogramming in "resistant" breast carcinoma cells. Cancer Res (2009) 1.98
Maternal traces of deep common ancestry and asymmetric gene flow between Pygmy hunter-gatherers and Bantu-speaking farmers. Proc Natl Acad Sci U S A (2008) 1.96
Effects of traditional and western environments on prevalence of type 2 diabetes in Pima Indians in Mexico and the U.S. Diabetes Care (2006) 1.96
Preoperative therapy with trastuzumab and paclitaxel followed by sequential adjuvant doxorubicin/cyclophosphamide for HER2 overexpressing stage II or III breast cancer: a pilot study. J Clin Oncol (2003) 1.96
Predictability of adjuvant trastuzumab benefit in N9831 patients using the ASCO/CAP HER2-positivity criteria. J Natl Cancer Inst (2011) 1.94
Failure of higher-dose paclitaxel to improve outcome in patients with metastatic breast cancer: cancer and leukemia group B trial 9342. J Clin Oncol (2004) 1.83
Linkage disequilibrium patterns vary substantially among populations. Eur J Hum Genet (2005) 1.73
Rare BRCA1 haplotypes including 3'UTR SNPs associated with breast cancer risk. Cell Cycle (2011) 1.64
Structural diversity and African origin of the 17q21.31 inversion polymorphism. Nat Genet (2012) 1.62
Geographic and haplotype structure of candidate type 2 diabetes susceptibility variants at the calpain-10 locus. Am J Hum Genet (2002) 1.61
Refined geographic distribution of the oriental ALDH2*504Lys (nee 487Lys) variant. Ann Hum Genet (2009) 1.49
Genotyping and haplotyping of CYP2C19 functional alleles on thin-film biosensor chips. Pharmacogenet Genomics (2007) 1.49
The evolution and population genetics of the ALDH2 locus: random genetic drift, selection, and low levels of recombination. Ann Hum Genet (2004) 1.49
Evidence of positive selection on a class I ADH locus. Am J Hum Genet (2007) 1.48
SNPs for a universal individual identification panel. Hum Genet (2010) 1.42
Biologic, demographic, and social factors affecting triple negative breast cancer outcomes. Clin J Oncol Nurs (2015) 1.39
Candidate SNPs for a universal individual identification panel. Hum Genet (2007) 1.39
Geographically separate increases in the frequency of the derived ADH1B*47His allele in eastern and western Asia. Am J Hum Genet (2007) 1.37
Distinct human papillomavirus type 16 methylomes in cervical cells at different stages of premalignancy. Virology (2009) 1.36
On the use of DNA pooling to estimate haplotype frequencies. Genet Epidemiol (2003) 1.33
Vegetable Intake in College-Aged Adults Is Explained by Oral Sensory Phenotypes and TAS2R38 Genotype. Chemosens Percept (2010) 1.32
The distribution and most recent common ancestor of the 17q21 inversion in humans. Am J Hum Genet (2010) 1.31
Loss of the retinoblastoma binding protein 2 (RBP2) histone demethylase suppresses tumorigenesis in mice lacking Rb1 or Men1. Proc Natl Acad Sci U S A (2011) 1.28
Haplotype block structures show significant variation among populations. Genet Epidemiol (2004) 1.28
VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin Cancer Res (2008) 1.27
Genetic differences in human circadian clock genes among worldwide populations. J Biol Rhythms (2008) 1.27
Significant variation in haplotype block structure but conservation in tagSNP patterns among global populations. Eur J Hum Genet (2007) 1.26
Analyses of a set of 128 ancestry informative single-nucleotide polymorphisms in a global set of 119 population samples. Investig Genet (2011) 1.22
Obsessive-compulsive symptom dimensions in affected sibling pairs diagnosed with Gilles de la Tourette syndrome. Am J Med Genet B Neuropsychiatr Genet (2003) 1.21
Intra- and interpopulation genotype reconstruction from tagging SNPs. Genome Res (2006) 1.21
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial. J Clin Oncol (2011) 1.21
Signatures of purifying and local positive selection in human miRNAs. Am J Hum Genet (2009) 1.18
MSVM-RFE: extensions of SVM-RFE for multiclass gene selection on DNA microarray data. Bioinformatics (2007) 1.18
Single-nucleotide polymorphism genotyping on optical thin-film biosensor chips. Proc Natl Acad Sci U S A (2003) 1.16
Genomewide scan of hoarding in sib pairs in which both sibs have Gilles de la Tourette syndrome. Am J Hum Genet (2002) 1.13
Use of autosomal loci for clustering individuals and populations of East Asian origin. Hum Genet (2005) 1.13
Possible epistatic role of ADH7 in the protection against alcoholism. Am J Med Genet B Neuropsychiatr Genet (2004) 1.13
ALFRED: an allele frequency resource for research and teaching. Nucleic Acids Res (2011) 1.12
PAM50 proliferation score as a predictor of weekly paclitaxel benefit in breast cancer. Breast Cancer Res Treat (2013) 1.10
Downstream targets of HOXB4 in a cell line model of primitive hematopoietic progenitor cells. Blood (2010) 1.10
HAPLOT: a graphical comparison of haplotype blocks, tagSNP sets and SNP variation for multiple populations. Bioinformatics (2005) 1.10
Evolutionary insights into the high worldwide prevalence of MBL2 deficiency alleles. Hum Mol Genet (2006) 1.09
Epidemiology. DNA identifications after the 9/11 World Trade Center attack. Science (2005) 1.09
A global view of the OCA2-HERC2 region and pigmentation. Hum Genet (2011) 1.08
Triple negative breast cancer: current understanding of biology and treatment options. Curr Opin Obstet Gynecol (2008) 1.07
Lineage specificity of gene expression patterns. Proc Natl Acad Sci U S A (2004) 1.07
Optimal tumor sampling for immunostaining of biomarkers in breast carcinoma. Breast Cancer Res (2011) 1.07
Considerable haplotype diversity within the 23kb encompassing the ADH7 gene. Alcohol Clin Exp Res (2005) 1.05
Inference of human continental origin and admixture proportions using a highly discriminative ancestry informative 41-SNP panel. Investig Genet (2013) 1.04
Novel anti-filamin-A antibody detects a secreted variant of filamin-A in plasma from patients with breast carcinoma and high-grade astrocytoma. Cancer Sci (2009) 1.02
Population variation in linkage disequilibrium across the COMT gene considering promoter region and coding region variation. Hum Genet (2002) 1.01
Haplotype evolution of SLITRK1, a candidate gene for Gilles de la Tourette syndrome. Am J Med Genet B Neuropsychiatr Genet (2008) 0.99
The HER2 extracellular domain as a prognostic and predictive factor in breast cancer. Clin Breast Cancer (2002) 0.98
Genetic landscape of Eurasia and "admixture" in Uyghurs. Am J Hum Genet (2009) 0.98
Positive selection in MAOA gene is human exclusive: determination of the putative amino acid change selected in the human lineage. Hum Genet (2004) 0.98
Population-specific variation in haplotype composition and heterozygosity at the POLB locus. DNA Repair (Amst) (2009) 0.98
HER-2 gene amplification correlates with higher levels of angiogenesis and lower levels of hypoxia in primary breast tumors. Clin Cancer Res (2004) 0.97
Declining plasma fibrinogen alpha fragment identifies HER2-positive breast cancer patients and reverts to normal levels after surgery. J Proteome Res (2006) 0.96
Selection on the human bitter taste gene, TAS2R16, in Eurasian populations. Hum Biol (2011) 0.96
Ethnic related selection for an ADH Class I variant within East Asia. PLoS One (2008) 0.96
Three-drug combination regimen in pancreatic cancer treatment: are we there yet? JOP (2011) 0.96
Progress toward an efficient panel of SNPs for ancestry inference. Forensic Sci Int Genet (2014) 0.95
Worldwide population variation and haplotype analysis at the serotonin transporter gene SLC6A4 and implications for association studies. Biol Psychiatry (2013) 0.95
A proline-threonine substitution in codon 351 of ADH1C is common in Native Americans. Alcohol Clin Exp Res (2002) 0.94
Long-term outcomes and clinicopathologic differences of African-American versus white patients treated with breast conservation therapy for early-stage breast cancer. Cancer (2008) 0.94
Current sequencing technology makes microhaplotypes a powerful new type of genetic marker for forensics. Forensic Sci Int Genet (2014) 0.92
Quantitative measurements of HER2 and phospho-HER2 expression: correlation with pathologic response to neoadjuvant chemotherapy and trastuzumab. BMC Cancer (2014) 0.91